Sepsis Awareness Month is in September. SEP for Sepsis.
SEP for September – making September the perfect month for Sepsis Awareness Month
30 Days to Highlight Sepsis
September is Sepsis Awareness Month and for 30 days, Sepsis Alliance www.sepsis.org and sepsis advocates pull out all the stops to spread the word about what sepsis is, what it does, and how we can make a difference and save lives.
Faces of Sepsis:
Sepsis hits home and is no stranger to the Foundress of the C diff Foundation or to the millions of families who have lost loved ones from Sepsis. Loosing a loved one from Septic Shock with C.diff. involvement is devastating for any family. The C Diff Foundation supports and joins the organizations raising Sepsis awareness worldwide and we encourage everyone to join in the global efforts being made to help save lives.
Click on the Logo below to listen to the Podcast from a live broadcast on “C. diff. Spores and More” Global Broadcasting Network “Sepsis; Number One Preventable Cause of Death Worldwide” with guests Dr. Tex Kissoon, MD,a well-known doctor from Canada, will provide us with the insight into the global phenomenon of Sepsis. Sepsis affects more than 30 million lives per year yet it is almost unknown to the general public and is quite often misdiagnosed by medical professionals worldwide. The reasons of why that is with the “why” Sepsis is so deadly, and what you can do to increase Sepsis awareness– will be discussed in the next 60 minutes. Dr. Kissoon is joined by Ray Schachter, a Sepsis survivor who has dedicated all of his available time to combating and raising awareness of Sepsis worldwide. Both are members of the Global Sepsis Alliance, which has established World Sepsis Day on September 13th every year to raise awareness for Sepsis worldwide.
World Sepsis Day is September 13th
Free online congress on September 8- 9, 2016
Saving patients from sepsis is a race against time
CDC calls sepsis a medical emergency; encourages prompt action for prevention, early recognition
Sepsis is caused by the body’s overwhelming and life-threatening response to an infection and requires rapid intervention. It begins outside of the hospital for nearly 80 percent of patients. According to a new Vital Signs report released by CDC, about 7 in 10 patients with sepsis had used health care services recently or had chronic diseases that required frequent medical care. These represent opportunities for healthcare providers to prevent, recognize, and treat sepsis long before it can cause life-threatening illness or death.
“When sepsis occurs, it should be treated as a medical emergency,” said CDC Director Tom Frieden, M.D., M.P.H. “Doctors and nurses can prevent sepsis and also the devastating effects of sepsis, and patients and families can watch for sepsis and ask, ‘could this be sepsis?’”
Certain people with an infection are more likely to get sepsis, including people age 65 years or older, infants less than 1 year old, people who have weakened immune systems, and people who have chronic medical conditions (such as diabetes). While much less common, even healthy children and adults can develop sepsis from an infection, especially when not recognized early. The signs and symptoms of sepsis include: shivering, fever, or feeling very cold; extreme pain or discomfort; clammy or sweaty skin; confusion or disorientation; shortness of breath and a high heart rate.
According to the Vital Signs report, infections of the lung, urinary tract, skin, and gut most often led to sepsis. In most cases, the germ that caused the infection leading to sepsis was not identified. When identified, the most common germs leading to sepsis were Staphylococcus aureus, Escherichia coli (E. coli), and some types of Streptococcus.
Health care providers, patients and their family members can work as a team to prevent sepsis.
Health care providers play a critical role in protecting patients from infections that can lead to sepsis and recognizing sepsis early. Health care providers can:
· Prevent infections. Follow infection control requirements (such as handwashing) and ensure patients to get recommended vaccines (e.g., flu and pneumococcal).
· Educate patients and their families. Stress the need to prevent infections, manage chronic conditions, and, if an infection is not improving, promptly seek care. Don’t delay.
· Think sepsis. Know the signs and symptoms to identify and treat patients earlier.
· Act fast. If sepsis is suspected, order tests to help determine if an infection is present, where it is, and what caused it. Start antibiotics and other recommended medical care immediately.
· Reassess patient management. Check patient progress frequently. Reassess antibiotic therapy 24-48 hours or sooner to change therapy as needed. Determine whether the type of antibiotics, dose, and duration are correct.
CDC is working on five key areas related to sepsis:
· Increasing sepsis awareness by engaging clinical professional organizations and patient advocates.
· Aligning infection prevention, chronic disease management, and appropriate antibiotic use to promote early recognition of sepsis.
· Studying risk factors for sepsis that can guide focused prevention and early recognition.
· Developing tracking for sepsis to measure impact of successful interventions.
· Preventing infections that may lead to sepsis by promoting vaccination programs, chronic disease management, infection prevention, and appropriate antibiotic use.
To read the entire Vital Signs report visit: www.cdc.gov/vitalsigns/sepsis.
For more information on sepsis and CDC’s work visit: www.cdc.gov/sepsis.
Summit Therapeutics is to present further data showing the superiority of its new antibiotic for hospital superbug C.diff. over the standard of care medicine.
The additional data on Summit’s ridinilazole versus vancomycin comes from the from the Phase 2 CoDIFy trial and will be heard at the 26th European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID).
(ECCMID 2016 Will be hosted in Amsterdam from 9 – 12 April )
Taking the antibiotic ridinilazole resulted in a marked reduction in rates of C. diff. (CDI) recurrence as compared to vancomycin (14.3% versus 34.8%) the drug discovery firm will say.
This result comes on top of t previously reported statistical superiority in ‘sustained clinical response’ rates of ridinilazole over vancomycin (66.7% compared to 42.4%) for treating the disease.
Sustained clinical response is defined as clinical cure at the end of treatment and no recurrence of the condition in 30 days after therapy.
C. diff is a serious threat in hospitals and care homes and there are between 450000 and 700000 cases in the US annually.
Recurrence is a key problem as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs.
To read the total article, click on the following link:
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.
We are pleased to announce that Dr. Hudson Garrett, Jr., PhD, MSN, MPH, FNP, CSRN, VA-BC, CDONA,FACONA,DON-CLTC
Chairman of the Education Committee of the C Diff Foundation.
Dr. Garrett will be overseeing, and developing the Foundation’s volunteer patient advocate (VPA) program, healthcare workshops and programs for both patients and clinicians. As a member of the Foundation’s Research and Development committee, Dr. Garrett provided great support.
Dr. Garrett is aiding in the development of patient and clinician focused C.diff. Spores and More Global Broadcasting Network episodes and discussing leading healthcare
topics — as our global listeners span across 56 countries and counting.
Dr. Hudson Garrett is currently employed as the VP, Clinical Affairs for PDI, Inc. and NIce-Pak, and is responsible for the global Clinical Affairs program and also the Medical Science Liaison program for all divisions within the company. He holds a Bachelor of Science degree in Biology/Chemistry and Nursing, a dual Masters in Nursing and Public Health, Post-Masters Certificate as a Family Nurse Practitioner, a Post-Masters Certificate in Infection Prevention and Infection Control and a PhD in Healthcare Administration and Policy. He has completed the Johns Hopkins Fellows Program in Hospital Epidemiology and Infection Control, and the CDC Fundamentals of Healthcare Epidemiology program, and is board certified in family practice, critical care, vascular assess, moderate sedation, legal nurse consulting, and a director of nursing in long term care. Dr. Garrett is also a Fellow in the Academy of National Associations of Directors of Nursing Administration in Long Term Care.
Dr. Garrett currently serves on the Society for Healthcare Epidemiology of America Pediatric Subcommittee, as President of the Board of Directors, for the Vascular Access Certification Corporation, is the past Education Chair for the Greater Atlanta Chapter of the Association for Professionals In Infection Control and Epidemiology Board of Directors, a National Faculty Member for the Emergency Care and Safety Institute, President of the Board of Directors for the Southeast Chapter of the Infusion Nurses Society, the Industry Liaison for the Board of Directors for the Association for the Healthcare Environment, a member of the Clinical Practices Advisory Committee for the Association for Vascular Access, and a past member of the Recommended Practices Advisory Board for the Association of Peri-operative Registered Nurses. In addition, Dr. Garrett received a Presidential Citation from the Society of Critical Care Medicine in 2011 in recognition for his advancement of critical care nursing and infection prevention.
He also serves as the Industry Liaison for the Assoc. for the Healthcare Environment Board of Directors, is the lead faculty member for the Assoc. for the Healthcare Environment’s Online Certificate Program in the Essentials of Infection Prevention for Environmental Services Professionals, two time nominee for the Assoc. for Vascular Access Herbst Award, served as a reviewer for the 2013 Best Practices in Adult Peripheral Vascular Access Resource Guide for the Assoc. of Vascular Access, currently the second author for the second revision of the Assoc. for Vascular Access Pediatric Special Interest Organization Guidelines which is scheduled to be released in 2015, also an author for the AVA CVC Best Practices Resource guide. He was also recognized as a 2013 “Who’s who in Infection Prevention and Control” by Infection Control Magazine.
Dr. Garrett has published in many publications including Infection Control Today, Managing Infection Control, Provider, The Assisted Living Journal, and in the American Journal of Long Term Care, American Journal of Critical Care, and also in several Mosby Saunders medical textbooks to name a few.
He is currently an active member of many professional organizations including:
Association of Professionals in Infection Control and Epidemiology, the Association for the Healthcare Environment, the Society of Hospital Epidemiology of America, Infectious Disease Society of America, Association for Vascular Access, Infusion Nurses Society, American Society for Professionals in Patient Safety, Society of Critical Care Medicine, Assoc. for Peri-operative Registered Nurses, American Medical Directors Assoc., American Assoc. of Moderate Sedation Nurses, American College of Healthcare Executives, Nat’l Assoc. of Directors of Nursing in Long Term Care, American Assoc. for Long Term Care Nursing, American Assoc. of Nurse Assessment Coordinators, and American Academy of Nurse Practitioners.
Dr. Hudson Garrett is passionate about delivering unsurpassed material and provides excellent support on every level. We are fortunate to have Dr. Hudson Garrett, Jr. leading the Foundation’s Education Committee. Please join us in congratulating him on his new, well-deserved position.
Nancy C. Caralla, Founder, Executive Director
With the C Diff Foundation Board of Directors, Chairpersons and Committee Members